ReviewCureus2025
From One-Size-Fits-All to Precision Care: Biomarker-Guided Lung Recruitment in Acute Respiratory Distress Syndrome.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) poses the problem of ventilating a heterogeneous lung with both well-aerated and collapsed lung units with different elastances. The interfaces between open and closed alveoli are exposed to amplified stress, thereby increasing the probability of ventilator-induced lung injury (VILI). An "open lung approach" of opening closed alveoli with recruitment maneuvers (RM) and keeping them open with high positive end-expiratory pressure (PEEP) was proposed as a promising method of homogenizing gas distribution and reducing the risk of VILI. This approach has been shown to improve oxygenation consistently. However, studies have found conflicting results on the effect of RM on patient outcomes, with the latest randomized controlled trial (RCT) showing increased mortality with the use of RMs. The failure of randomized trials testing RMs may be due to the inclusion of a heterogeneous group of ARDS patients without focusing on the ARDS phenotypes most likely to benefit from RM. Recent exploration of ARDS inflammatory phenotypes and the differential effect of therapeutics, especially high PEEP, based on phenotypes, raises the possibility of personalizing RMs to identify patient subgroups likely to benefit from the procedure. Findings of the research measuring inflammatory cytokines in bronchoalveolar lavage (BAL) fluid before and 24 hours after RMs in ARDS patients indicate the need for further research to define the role of inflammatory biomarkers in individualizing ventilation strategies in ARDS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.